Paper · 42947166
Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial.
Goplen D and 10 others. Biomark Res, 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial. Papers, record 42947166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42947166
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial.
- Journal
- Biomark Res
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-30
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| # 190170 | Norwegian Cancer Society | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03643549 | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References50
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19,554,337 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. | Acta Neuropathol | 2009 | https://conductscience.org/library/papers/19554337 | PubMed |
| 2 | 12,516,957 | Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. | Mol Cancer Ther | 2002 | https://conductscience.org/library/papers/12516957 | PubMed |
| 3 | 8,259,215 | A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. | Nature | 1993 | https://conductscience.org/library/papers/8259215 | PubMed |
| 4 | 38,183,430 | Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. | Acta Neuropathol | 2024 | https://conductscience.org/library/papers/38183430 | PubMed |
| 5 | 18,985,363 | Analysis of the IDH1 codon 132 mutation in brain tumors. | Acta Neuropathol | 2008 | https://conductscience.org/library/papers/18985363 | PubMed |
| 6 | 10,521,434 | The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. | J Biol Chem | 1999 | https://conductscience.org/library/papers/10521434 | PubMed |
| 7 | 17,591,937 | Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. | J Mol Diagn | 2007 | https://conductscience.org/library/papers/17591937 | PubMed |
| 8 | 24,335,854 | The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). | Ann Oncol | 2014 | https://conductscience.org/library/papers/24335854 | PubMed |
| 9 | 8,153,634 | A cell cycle regulator potentially involved in genesis of many tumor types. | Science | 1994 | https://conductscience.org/library/papers/8153634 | PubMed |
| 10 | 19,435,942 | IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. | Neuro Oncol | 2009 | https://conductscience.org/library/papers/19435942 | PubMed |
1 to 10 of 50
See all 50 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL325041 | ChEMBL |
| TEMOZOLOMIDE | CHEMBL810 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL810 | ChEMBL |
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42947166
GET https://conductscience.org/api/papers/v1/42947166/references?page=2